The price of MoonLake Immunotherapeutics (NASDAQ:MLTX) shares last traded on Wall Street rose 2.32% to $11.49.
Based on available information, 5 analysts follow MoonLake Immunotherapeutics (NASDAQ:MLTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $28.00 and a low of $16.00, we find $21.00. Given the previous closing price of $11.23, this indicates a potential upside of 87.0 percent. MLTX stock price is now 14.79% away from the 50-day moving average and 49.33% away from the 200-day moving average. The market capitalization of the company currently stands at $614.26M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
Among analysts, 0 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $21.50 as their price target over the next twelve months.
With the price target of $16, Jefferies recently initiated with Buy rating for MoonLake Immunotherapeutics (NASDAQ: MLTX). On August 25, 2022, SVB Leerink recently initiated its ‘Outperform’ rating on the stock quoting a target price of $17, while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
A total of 0.25% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MLTX stock. A new stake in MoonLake Immunotherapeutics shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $3,849,000. TEKLA CAPITAL MANAGEMENT LLC invested $3,447,000 in shares of MLTX during the first quarter. In the first quarter, BALYASNY ASSET MANAGEMENT LLC acquired a new stake in MoonLake Immunotherapeutics valued at approximately $1,148,000. MORGAN STANLEY acquired a new stake in MLTX for approximately $36,000. In total, there are 30 active investors with 94.60% ownership of the company’s stock.
A candlestick chart of MoonLake Immunotherapeutics (NASDAQ: MLTX) showed a price of $11.23 on Monday morning. During the past 12 months, MoonLake Immunotherapeutics has had a low of $4.25 and a high of $15.19. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 14.70, and a quick ratio of 14.70. The fifty day moving average price for MLTX is $10.01 and a two-hundred day moving average price translates $7.67 for the stock.
The latest earnings results from MoonLake Immunotherapeutics (NASDAQ: MLTX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.34, beating analysts’ expectations of -$0.54 by 0.2. This compares to -$2.63 EPS in the same period last year. The company reported revenue of $14.77 million for the quarter, compared to $6.27 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 135.69 percent.
MoonLake Immunotherapeutics(MLTX) Company Profile
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
